Huons BioPharma is about to sign a contract with a new partner to market its botulinum toxin product, Hutox, in the European market.Huons BioPharma, a subsidiary of Huons Global, said Tuesday that the contract signing with its German partner, known only as H, has gone into a countdown.According to H
Genexine said Monday that it signed an agreement with Toolgen to co-develop and commercialize CAR-NK cell gene therapy using the latter’s CRISPR/Cas9 technology.The two companies will co-own patent rights, utility model rights, trademark rights, and R&D data resulting from their co-development at a
Celltrion said that an animal efficacy test for Regkirona, its Covid-19 antibody treatment, showed efficacy in treating the Gamma variant originating in Brazil.In the study, the company injected Regkirona in 55 laboratory mice infected with Gamma variant.Compared to the control group that did not re
Chong Kun Dang said it would export Nesbell, an anemia treatment biosimilar (Original: Nesp), to six Middle East countries, through Menagen, an Omani pharmaceutical company.Under the contract, Chong Kun Dang will supply finished Nesbell products to Menagen and receive a down payment and milestones f
SK Biopharmaceuticals said it aims to grow into one of the top 10 global healthcare companies by 2030 in its online presentation on Friday.The company will focus on expanding its portfolios in the U.S., developing different regional business models, finding additional areas for creating new pipeline
“With the inauguration of the Biden administration, Korean pharmaceutical and biotech companies are expected to face both challenges and opportunities.”Kang Ryung-woo, senior research director at the Korea National Enterprise for Clinical Trials (KoNECT), said this and other remarks at an online con
Hanmi Pharmaceutical said that efpeglenatide, its long-acting diabetes biologic drug, significantly reduced incidences of major adverse cardiovascular events (MACE) and kidney disease in phase 3 clinical trials.According to Hanmi, Sanofi presented the results of the global, large-scale cardiovascula
Samsung Bioepis said that the European Medicines Agency’s (EMA) Committee for Human Medical Products (CHMP) issued a positive scientific opinion on Byooviz, a biosimilar candidate referencing Lucentis (Ingredient: Ranibizumab)According to the company, the positive opinion comes only eight months aft
Korean drugmakers said they had one-on-one partnering meetings with multinational pharmaceutical companies at the virtual Bio International Convention 2021 (BIO USA 2021) to develop their newest pipelines.Due to the prolonged Covid-19 pandemic, the event took place in a virtual format, just like las
Skin bank generally refers to an organization that removes skin from donors, stores it, and reuses it as a graft for patients.Tego Science, a Korean company that produces cultured epidermis for wound healing, runs the nation’s only cell bank, collecting allogeneic cells from patients and culture to
Celltrion said that an animal efficacy test for Regkirona, its Covid-19 antibody treatment, showed efficacy in treating the South African beta variants.In the study, the company injected Regkirona in 50 laboratory mice infected with Covid-19.Compared to the control group that did not receive any dru
ToolGen, a company specializing in gene editing, said it has signed a joint research deal with T&R Biofab, a three-dimensional (3D) bioprinting company, to develop induced pluripotent stem cells (iPSC) to overcome immune rejection.Under the accord, the two companies will rectify genes related to imm
What should Korea do to become a global vaccine manufacturing hub?Covid-19 vaccine manufacturing was the key issue in the recent summit between Korean President Moon Jae-in and U.S. President Joe Biden and the G7 summit in the U.K.To discuss how to nurture the Korean vaccine industry, healthcare ind
Helixsmith said Wednesday that it has acquired a patent for its technology of new plasmid deoxyribonucleic acid (DNA) therapy in China.With the newly registered patent, the company secured exclusive rights of therapeutic techniques for treating patients with peripheral artery disease using a combina
Domestic biopharmaceutical companies have set about to expand their overseas production bases of cell and gene therapies, which are emerging as a new promising sector, according to industry sources.Korean drugmakers show interest in regenerative medicines, including cellular and genetic therapies, b
Celltrion said that it has confirmed the efficacy and safety of Regkirona, its Covid-19 antibody treatment, presenting the top-line results of its global phase 3 clinical trial of the treatment.The company had conducted trials on 1,315 mild and moderate Covid-19 patients in 13 countries, including K
“Korea has been a ‘barren land’ for CAR-T (chimeric antigen receptor-T) cell therapy. But after Curocell won approval for a clinical trial this year for the first time, the door to the market has opened.”So said Curocell CEO Kim Gun-soo, expressing his pride at the Invest Fair during Bio Korea 2021,
Institute for Basic Science (IBS) Center for RNA Research and Seoul National University (SNU) School of Biological Sciences hosted an online meeting, ‘2021 IBS-SNU Mini-symposia on RNA Biology and Therapeutics,” on Wednesday.RNA, or ribonucleic acids, are central components of genetic information in
An international conference on the bio-health industry has kicked off in Seoul, where innovative technologies will show their leading roles in the post-Covid-19 era.The Ministry of Health and Welfare said it would hold Bio Korea 2021 at the COEX C Hall in southern Seoul from Wednesday to Friday.For
Celltrion said Monday that it has acquired a controlling stake of Iksuda Therapeutics, a British antibody-drug conjugate developer, to secure ADC-based new drug pipelines."Celltrion, together with the Mirae Asset Group, has signed a contract to invest $47 million (53 billion won) into Iksuda and bec